Erectile dysfunction: oral pharmacotherapy options

Vitezić, Dinko; Pelčić, Jasenka Mršić

doi:10.5414/cpp40393

Cited by 30 publications

(20 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…122 Drug-induced rhinitis [Summary Statement 28] Drug-induced rhinitis may be caused by ACE inhibitors, 123 a-receptor antagonists used in the treatment of benign prostatic hypertrophy, 124 and phosphodiesterase-5 selective inhibitors used for treatment of erectile dysfunction. 125 There is no direct evidence that the current combined oral contraceptive pills cause nasal symptoms. 126 Aspirin and other NSAIDs may produce rhinorrhea as an isolated symptom or as part of aspirin-exacerbated respiratory disease (AERD), formerly termed ''Samter's triad.''…”

Section: Executive Summary Definition Of Rhinitis [Summary Statement 1]mentioning

confidence: 99%

“…124 Phosphodiesterase-5-selective inhibitors used for treatment of erectile dysfunction can cause nasal congestion. 125 Phentolamine mesylate, an a-1 and a-2-selective adrenergic receptor antagonist, has been reported to cause rhinitis symptoms in 7.7% of patients treated for erectile dysfunction. 800 Although oral contraceptives have long been implicated as causes of nasal symptoms, a recent study found no nasal physiologic effects on female patients receiving a modern combined oral contraceptive pill.…”

Section: Drug-induced Rhinitismentioning

confidence: 99%

See 1 more Smart Citation

The diagnosis and management of rhinitis: An updated practice parameter

Wallace¹,

Dykewicz²,

Bernstein³

et al. 2008

Journal of Allergy and Clinical Immunology

942

953

View full text Add to dashboard Cite

Section: Executive Summary Definition Of Rhinitis [Summary Statement 1]mentioning

confidence: 99%

Section: Drug-induced Rhinitismentioning

confidence: 99%

The diagnosis and management of rhinitis: An updated practice parameter

Wallace¹,

Dykewicz²,

Bernstein³

et al. 2008

Journal of Allergy and Clinical Immunology

942

953

View full text Add to dashboard Cite

“…Among the cGMP-specific PDEs, PDE6 is structurally most similar to PDE5: they share > 40% of their catalytic domain. This accounts for the well-documented side effect of a transient disturbance in visual function with sildenafil [43] .…”

Section: Pde5 Inhibitorsmentioning

confidence: 98%

Novel phosphodiesterase-5 (PDE5) inhibitors in the alleviation of erectile dysfunction due to diabetes and ageing-induced oxidative stress

Gür

Sikka

2008

Expert Opinion on Investigational Drugs

View full text Add to dashboard Cite

Background : Diabetes and ageing are associated with erectile dysfunction (ED). Under these conditions, increased oxidative stress produces superoxide ions, which in turn suppresses the nitric oxide-cyclic guanosine monophosphate pathway. The phophodiesterase-5 (PDE5) inhibitors still remain ineffective in 15 -57% of impotent men. Objective : To identify the efficacy of conventional and novel PDE5 inhibitors on oxidative stress involved in diabetes and ageing. Methods : An electronic search of the literature was conducted to review published information relating diabetes and ageing to ED and to cover latestage developments of novel PDE5 inhibitors. Results/conclusion : Safe and more efficacious alternatives that can modulate PDE5 levels in ED regarding oxidative stress conditions are needed. Included in this review are updates on the new PDE5 inhibitors avanafil, udenafil, SLx-2101, and mirodenafil.

show abstract

“…ED is a widespread condition with a markedly negative impact on quality of life. It is estimated that 10 to 30 million men in the United States and more than 100 million worldwide experience some form of ED 1 , 2 . This condition is strongly age associated, and according to the community‐based Massachusetts Male Aging Study, the prevalence of ED in men 40 to 70 years old is 52% 2 .…”

mentioning

confidence: 99%

The Clinical Pharmacokinetics of Phosphodiesterase‐5 Inhibitors for Erectile Dysfunction

Gupta

Kovar

Meibohm

2005

The Journal of Clinical Pharma

160

161

View full text Add to dashboard Cite

Differences in the clinical pharmacology of the 3 currently available oral phosphodiesterase-5 (PDE5) inhibitors, sildenafil, vardenafil, and tadalafil, are largely determined by their clinical pharmacokinetics as well as their PDE inhibitory activity profile. This review comparatively discusses the major characteristics of the pharmacokinetic profile of all 3 PDE5 inhibitors, including bioavailability and rate of absorption, Biopharmaceutical Classification System categorization, elimination mechanisms, and metabolic profile including active metabolites, as well as the drug-drug interaction potential and modification of pharmacokinetic properties under selected physiologic and pathophysiologic conditions. The review is aimed at providing comparative clinical pharmacology data to allow for scientifically rational, evidence-based prescribing and dosing decisions regarding the clinical use of these medications for the treatment of erectile dysfunction.

show abstract

Erectile dysfunction: oral pharmacotherapy options

Cited by 30 publications

References 0 publications

The diagnosis and management of rhinitis: An updated practice parameter

The diagnosis and management of rhinitis: An updated practice parameter

Novel phosphodiesterase-5 (PDE5) inhibitors in the alleviation of erectile dysfunction due to diabetes and ageing-induced oxidative stress

The Clinical Pharmacokinetics of Phosphodiesterase‐5 Inhibitors for Erectile Dysfunction

Contact Info

Product

Resources

About